Increased plasma levels of damage-associated molecular patterns during systemic anticancer therapy in patients with advanced lung cancer
暂无分享,去创建一个
N. Hamada | Y. Nakanishi | I. Okamoto | Tomohiro Ogawa | Kentaro Tanaka | Y. Yoneshima | K. Ota | E. Iwama | Hironori Tsutsumi | Y. Shiraishi | H. Inoue | H. Ogata | Hiroyuki Ando | K. Okamura | T. Nakanishi | S. Shinozaki | Shinichi Kimura | Aiko Hirayama | Maako Nakajima | K. Uryu
[1] F. Marincola,et al. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death , 2020, Journal for ImmunoTherapy of Cancer.
[2] A. Jemal,et al. Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.
[3] T. Doman,et al. The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy , 2019, Clinical Cancer Research.
[4] S. Yamada,et al. Circulating histone H3 levels in septic patients are associated with coagulopathy, multiple organ failure, and death: a single-center observational study , 2019, Thrombosis Journal.
[5] S. Yamada,et al. Circulating histone H3 levels are increased in septic mice in a neutrophil-dependent manner: preclinical evaluation of a novel sandwich ELISA for histone H3 , 2018, Journal of Intensive Care.
[6] A. Mansfield,et al. First‐Line Atezolizumab plus Chemotherapy in Extensive‐Stage Small‐Cell Lung Cancer , 2018, The New England journal of medicine.
[7] A. Tafreshi,et al. Pembrolizumab plus Chemotherapy for Squamous Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.
[8] M. Garassino,et al. Pembrolizumab plus Chemotherapy in Lung Cancer. , 2018, The New England journal of medicine.
[9] Yi-long Wu,et al. Toward innovative combinational immunotherapy: A systems biology perspective. , 2018, Cancer treatment reviews.
[10] Federico Cappuzzo,et al. Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC , 2018, The New England journal of medicine.
[11] Yiran Huang,et al. The expression of DAMP proteins HSP70 and cancer-testis antigen SPAG9 in peripheral blood of patients with HCC and lung cancer , 2017, Cell Stress and Chaperones.
[12] E. Maggioli,et al. The restorative role of annexin A1 at the blood–brain barrier , 2016, Fluids and Barriers of the CNS.
[13] G. Kroemer,et al. Calreticulin Expression in Human Non-Small Cell Lung Cancers Correlates with Increased Accumulation of Antitumor Immune Cells and Favorable Prognosis. , 2016, Cancer research.
[14] R. Weissleder,et al. Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. , 2016, Immunity.
[15] L. Zitvogel,et al. Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. , 2015, Cancer cell.
[16] W. Weng,et al. Functional Roles of Calreticulin in Cancer Biology , 2015, BioMed research international.
[17] Shuanying Yang,et al. Elevated serum annexin A1 as potential diagnostic marker for lung cancer: a retrospective case-control study. , 2014, American journal of translational research.
[18] Xiaohuan Zou,et al. A sandwich enzyme-linked immunosorbent assay for detection of calreticulin in human serum. , 2013, Monoclonal antibodies in immunodiagnosis and immunotherapy.
[19] J. Hayball,et al. The multifunctional alarmin HMGB1 with roles in the pathophysiology of sepsis and cancer , 2013, Immunology and cell biology.
[20] H. Inoue,et al. Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments , 2013, Cell Death and Differentiation.
[21] Yichao Wang,et al. Serum Levels of Calreticulin in Correlation with Disease Activity in Patients with Rheumatoid Arthritis , 2013, Journal of Clinical Immunology.
[22] Laurence Zitvogel,et al. Immunogenic cell death in cancer therapy. , 2013, Annual review of immunology.
[23] L. Emens,et al. Chemoimmunotherapy: reengineering tumor immunity , 2013, Cancer Immunology, Immunotherapy.
[24] Abhishek D. Garg,et al. Immunogenic cell death and DAMPs in cancer therapy , 2012, Nature Reviews Cancer.
[25] H. Fujii,et al. Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma. , 2012, Cancer research.
[26] Abhishek D. Garg,et al. Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin , 2012, Cancer Immunology, Immunotherapy.
[27] C. Esmon,et al. Endogenous Histones Function as Alarmins in Sterile Inflammatory Liver Injury Through Toll-like Receptor 9 in Mice , 2011, Hepatology.
[28] Jun Xu,et al. Extracellular histones are major mediators of death in sepsis , 2009, Nature Medicine.
[29] P. van Endert,et al. Mechanisms of pre‐apoptotic calreticulin exposure in immunogenic cell death , 2009, The EMBO journal.
[30] Laurence Zitvogel,et al. Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy , 2007, Nature Medicine.
[31] M. Perretti,et al. Modulation of Phagocytosis of Apoptotic Neutrophils by Supernatant from Dexamethasone-Treated Macrophages and Annexin-Derived Peptide Ac2–261 , 2005, The Journal of Immunology.
[32] T. Misteli,et al. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation , 2002, Nature.
[33] C. Moorehead. All rights reserved , 1997 .
[34] P. Vandenabeele,et al. Immunogenic Apoptotic Cell Death and Anticancer Immunity. , 2016, Advances in experimental medicine and biology.
[35] M. Lotze,et al. HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells , 2011, Leukemia.